Optimind Pharma Corp. Announces Grant of Options
Optimind Pharma Corp. Announces Grant of Options
Toronto, Ontario--(Newsfile Corp. - March 10, 2023) - Optimind Pharma Corp. (CSE: OMND) (the "Company") wishes to announce that pursuant to its stock option plan, it has granted stock options to its directors, officers and consultants on March 8, 2023 to purchase up to 5,900,000 common shares of the Company at an exercise price of $0.05 per common share. The options have a term of four (4) years expiring on March 8, 2027.
安大略省多倫多--(Newsfile Corp.-2023年3月10日)-OptiMind Pharma Corp.(CSE:OMND)(“本公司”)希望宣佈,根據其股票期權計劃,它已於2023年3月8日向其董事、高級管理人員和顧問授予股票期權,以每普通股0.05美元的行使價購買至多590萬股公司普通股。這些期權的期限為四(4)年,於2027年3月8日到期。
About Optimind Pharma
關於OptiMind Pharma
Optimind Pharma is an emerging provider of psychedelic therapies. From specializing in prescribing medical cannabis, ketamine-assisted treatment, and other psychedelic-enhanced psychotherapy modalities, Optimind Pharma helps individuals suffering from PTSD, anxiety, depression, and other mental illnesses and disabilities.
OptiMind Pharma是一家新興的迷幻療法供應商。除了專門開出醫用大麻、氯胺酮輔助治療和其他迷幻增強型心理療法外,OptiMind Pharma還幫助患有創傷後應激障礙、焦慮、抑鬱和其他精神疾病和殘疾的個人。
Optimind exists to combine the power of psychedelic medicine with the science of psychology to provide legal psychedelic enhanced psychotherapy in a safe, controlled environment.
OptiMind的存在是為了將迷幻醫學的力量與心理科學結合起來,在安全、可控的環境中提供合法的迷幻增強心理治療。
To learn more about Optimind Pharma, visit .
要了解有關OptiMind Pharma的更多資訊,請訪問。
Caution regarding Forward-Looking Information:
有關前瞻性資訊的警告:
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward- looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and the emergency of additional competitors in the industry. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.
本新聞稿可能包含基於當前預期的前瞻性陳述和資訊。這些聲明不應被解讀為對公司未來業績或結果的保證。這類陳述涉及已知和未知的風險、不確定因素和其他因素,可能導致實際結果、業績或成就與這類陳述所暗示的大不相同。雖然這些陳述是基於管理層的合理假設,但不能保證這些假設將被證明是正確的。我們不承擔更新或修改它們以反映新事件或新情況的責任。此外,存在已知和未知的風險因素,可能導致公司的實際結果、業績或成就與本文中包含的前瞻性資訊明示或暗示的任何未來結果、業績或成就大不相同,例如但不限於對獲得監管部門批准的依賴;獲得與其技術相關的知識產權的能力;有限的經營歷史;一般商業、經濟、競爭、政治、監管和社會不確定性,以及行業中更多競爭對手的緊急情況。本文中的所有前瞻性資訊都受本警示聲明的約束,公司沒有義務修改或更新任何此類前瞻性資訊,也沒有義務公開宣佈對本文中包含的任何前瞻性資訊的任何修改結果,以反映未來的結果、事件或發展,除非法律要求。
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
加拿大證券交易所尚未對本新聞稿的充分性或準確性進行審查,也不承擔任何責任。
Media Contact: Tomas D Sipos | tdsipos@gmail.com | +1 647 991 1493
媒體聯繫人:託馬斯·D·西波斯|tdsipos@gmail.com|+1 647 991 1493
To view the source version of this press release, please visit
要查看本新聞稿的源版本,請訪問
譯文內容由第三人軟體翻譯。